Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Verrica Pharmaceuticals Inc. (VRCA)

6.53   0.32 (5.15%) 03-24 16:00
Open: 6.21 Pre. Close: 6.21
High: 6.9 Low: 6.21
Volume: 236,181 Market Cap: 273(M)

Technical analysis

as of: 2023-03-24 4:31:14 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 9.03     One year: 10.15
Support: Support1: 6.17    Support2: 5.14
Resistance: Resistance1: 7.73    Resistance2: 8.69
Pivot: 6.73
Moving Average: MA(5): 6.59     MA(20): 6.92
MA(100): 4.57     MA(250): 4.22
MACD: MACD(12,26): 0     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 11.5     %D(3): 20
RSI: RSI(14): 47.6
52-week: High: 9.22  Low: 1.76
Average Vol(K): 3-Month: 189 (K)  10-Days: 138 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ VRCA ] has closed above bottom band by 32.5%. Bollinger Bands are 35.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.91 - 6.95 6.95 - 6.98
Low: 6.12 - 6.16 6.16 - 6.21
Close: 6.46 - 6.53 6.53 - 6.59

Company Description

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Headline News

Fri, 24 Mar 2023
Analysts Issue Forecasts for Verrica Pharmaceuticals Inc.'s Q2 2023 ... - MarketBeat

Thu, 09 Mar 2023
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 ... - MyChesCo

Thu, 02 Mar 2023
The recent pullback must have dismayed Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders who own 39% of the company - Simply Wall St

Thu, 02 Mar 2023
NOVN: NDA Submitted - Yahoo Finance

Mon, 27 Feb 2023
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Resubmits NDA for ... - Best Stocks

Sun, 29 Jan 2023
Analysts Forecast Verrica Pharmaceuticals Inc. Earnings in the First ... - Best Stocks

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 42 (M)
Shares Float 20 (M)
% Held by Insiders 39.9 (%)
% Held by Institutions 25.9 (%)
Shares Short 242 (K)
Shares Short P.Month 233 (K)

Stock Financials

EPS -0.75
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.97
Profit Margin (%) -271.2
Operating Margin (%) -235.8
Return on Assets (ttm) -21.4
Return on Equity (ttm) -67.5
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0.19
Sales Per Share 0.21
EBITDA (p.s.) -0.5
Qtrly Earnings Growth 0
Operating Cash Flow -19 (M)
Levered Free Cash Flow -11 (M)

Stock Valuations

PE Ratio -8.83
PEG Ratio 0.1
Price to Book value 6.73
Price to Sales 30.26
Price to Cash Flow -14.66

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.